IMMP Immutep Limited

+0.03  (+2%)
Previous Close 1.71
Open 1.71
Price To Book 2.53
Market Cap 59,350,399
Shares 34,031,192
Volume 4,447
Short Ratio
Av. Daily Volume 25,716

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b PFS data due 1Q 2020.
Eftilagimod Alpha - Active Immunotherapy PAClitaxel (AIPAC)
Metastatic breast cancer (MBC)
Phase 1 updated data presented May 17, 2019 - ORR 50%.
Eftilagimod alpha and Keytruda (TACTI-mel)
Phase 2 initial data due mid-2019.
Eftilagimod alpha and Keytruda - TACTI-002
Non-small cell lung cancer; Head and neck cancer

Latest News

  1. The Daily Biotech Pulse: Jazz Buys Tumor Drug Program, Sanofi's BLA For Multiple Myeloma Drug Accepted, Positive Results For ViiV
  2. Immutep Raises A$10 Million Via Private Placement and Underwritten Entitlement Offer
  3. Edison Issues ADR Update On Immutep (IMMP)
  4. Immutep Completes Patient Enrolment of the AIPAC Phase IIb Clinical Trial in Metastatic Breast Cancer
  5. Immutep to Host Key Opinion Leader Call
  6. Immutep Announces Australian Patent Granted for Eftilagimod Alpha in Chemo-Immunotherapy
  7. Immutep Completes Recruitment of Initial Cohort in 1st Line NSCLC Patients for TACTI-002 Trial
  8. INSIGHT: First Patient Dosed in the 4th arm called “INSIGHT-004”
  9. Immutep Presentation at ASCO 2019
  10. What Kind Of Investor Owns Most Of Immutep Limited (ASX:IMM)?
  11. Immutep Announces European Patent Grant for Eftilagimod Alpha in Chemo-Immunotherapy
  12. Immutep Announces Data from Ongoing TACTI-mel Phase I Clinical Trial in Unresectable or Metastatic Melanoma
  13. Immutep Announces Upcoming Industry Conference Participation
  14. Immutep Limited (ASX:IMM): Are Analysts Optimistic?
  15. Edison Issues ADR Update on Immutep (IMMP)
  16. Immutep to Host Eftilagimod Alpha Clinical Development Update Global Webcast
  17. Immutep Announces United States Patent Grant for Eftilagimod Alpha in Cancer
  18. Immutep to Present IMP761 Preclinical Results in Global Webcast
  19. Immutep Presents Positive IMP761 Preclinical Results at 14th Congress of European Crohn’s and Colitis Organisation
  20. Immutep Shareholders Have Enjoyed A 52% Share Price Gain